advertisement
Abstract #14633 Published in IGR 8-4
Treating patients with primary open angle glaucoma or ocular hypertension with domestic and imported latanoprost drop: Comparison on efficacy and cost
Ma J-XInternational Journal of Ophthalmology 2006; 6: 895-897
AIM: To observe the efficacy and safety of domestic latanoprost eye drop and to research the comparisive cost-effectiveness of imported and domestic latanoprost eye drug. METHODS: Using randominzed, moonblind, paralleled group control study and choosing patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT), domestic latanoprost group was applied once a day in 18 patients of the experiment group and imported latanoprost (xalatan) in 14 patients of the control group for 4 weeks. The interlocular pressure (IOP), visual acuity, blood pressure, pulse, ouclar symptom and sign, and adverse reaction were observed. Using therapeutic efficacy observation and cost-effectiveness analysis, the two drugs were evaluated pharmacoeconomically. RESULTS: The daily average IOP (mean) in the experiment group decreased from (24.836) mmHg (1 mmHg = 0.133kPa) to (16.130) mmHg, and the maximum extent was 33%; The reduction in the control group was from (24.80) mmHg to (16.19) mmHg, and the maximum extent was 35%. The both groups significantly lowered IOP (P < 0.05); The between-group differences were not statistically significant at each time point (P > 0.05). Conjunctiva congestion increased obviously in both groups, but the treatment could continue. No other ocular or systemic adverse events related to the drugs were found. Cost-effectiveness analysis was used. The costs of the two groups were RMB119.00 and RMB70 respectively (P < 0.05); The IOP reduction extent rates were 35% and 33% (P > 0.05) respectively; The cost-effectiveness ratios were 3.39 and 2.11 respectively; And the incremental cost-effectiveness ratio of the imported group vs. the domestic group was 22.2. CONCLUSION: Both the domestic and imported latanoprost eye drop are safe and well-tolerated, and can effectively lowered IOP of patients with POAG or OHT, but the former is more economical than the latter.
Dr. J.-X. Ma, Department of Ophthalmology, Second Hospital, Hebei Medical University, Shijiazhuang 050021 Hebei Province, China
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
14 Costing studies; pharmacoeconomics